Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery : the multicenter, randomized, open-label ADMIT-NeP study
© 2024. The Author(s)..
BACKGROUND: For chronic pain after thoracic surgery, optimal timing of its diagnosis and effective treatment remains unresolved, although several treatment options are currently available. We examined the efficacy and safety of mirogabalin, in combination with conventional pain therapy (nonsteroidal anti-inflammatory drugs and/or acetaminophen), for treating peripheral neuropathic pain (NeP) after thoracic surgery.
METHODS: In this multicenter, randomized, open-label, parallel-group study, patients with peripheral NeP were randomly assigned 1:1 to mirogabalin as add-on to conventional therapy or conventional treatment alone.
RESULTS: Of 131 patients of consent obtained, 128 were randomized (mirogabalin add-on group, 63 patients; conventional treatment group, 65 patients). The least squares mean changes (95% confidence interval [CI]) in Visual Analogue Scale (VAS) score for pain intensity at rest from baseline to Week 8 (primary endpoint) were - 51.3 (- 54.9, - 47.7) mm in the mirogabalin add-on group and - 47.7 (- 51.2, - 44.2) mm in the conventional group (between-group difference: - 3.6 [95% CI: - 8.7, 1.5], P = 0.161). However, in patients with Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score (used for the screening of NeP) ≥ 12 at baseline, the greater the S-LANSS score at baseline, the greater the decrease in VAS score in the mirogabalin add-on group, while no such trend was observed in the conventional treatment group (post hoc analysis). This between-group difference in trends was statistically significant (interaction P value = 0.014). Chronic pain was recorded in 7.9% vs. 16.9% of patients (P = 0.171) at Week 12 in the mirogabalin add-on vs. conventional treatment groups, respectively. Regarding activities of daily living (ADL) and quality of life (QOL), changes in Pain Disability Assessment Scale score and the EQ-5D-5L index value from baseline to Week 8 showed significant improvement in the mirogabalin add-on group vs. conventional treatment group (P < 0.001). The most common adverse events (AEs) in the mirogabalin add-on group were dizziness (12.7%), somnolence (7.9%), and urticaria (3.2%). Most AEs were mild or moderate in severity.
CONCLUSIONS: Addition of mirogabalin to conventional therapy did not result in significant improvement in pain intensity based on VAS scores, but did result in significant improvement in ADL and QOL in patients with peripheral NeP after thoracic surgery.
TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs071200053 (registered 17/11/2020).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC cancer - 24(2024), 1 vom: 15. Jan., Seite 80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miyazaki, Takuro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 18.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-023-11708-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367161079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367161079 | ||
| 003 | DE-627 | ||
| 005 | 20240118232116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11708-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM367161079 | ||
| 035 | |a (NLM)38225552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miyazaki, Takuro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery |b the multicenter, randomized, open-label ADMIT-NeP study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: For chronic pain after thoracic surgery, optimal timing of its diagnosis and effective treatment remains unresolved, although several treatment options are currently available. We examined the efficacy and safety of mirogabalin, in combination with conventional pain therapy (nonsteroidal anti-inflammatory drugs and/or acetaminophen), for treating peripheral neuropathic pain (NeP) after thoracic surgery | ||
| 520 | |a METHODS: In this multicenter, randomized, open-label, parallel-group study, patients with peripheral NeP were randomly assigned 1:1 to mirogabalin as add-on to conventional therapy or conventional treatment alone | ||
| 520 | |a RESULTS: Of 131 patients of consent obtained, 128 were randomized (mirogabalin add-on group, 63 patients; conventional treatment group, 65 patients). The least squares mean changes (95% confidence interval [CI]) in Visual Analogue Scale (VAS) score for pain intensity at rest from baseline to Week 8 (primary endpoint) were - 51.3 (- 54.9, - 47.7) mm in the mirogabalin add-on group and - 47.7 (- 51.2, - 44.2) mm in the conventional group (between-group difference: - 3.6 [95% CI: - 8.7, 1.5], P = 0.161). However, in patients with Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score (used for the screening of NeP) ≥ 12 at baseline, the greater the S-LANSS score at baseline, the greater the decrease in VAS score in the mirogabalin add-on group, while no such trend was observed in the conventional treatment group (post hoc analysis). This between-group difference in trends was statistically significant (interaction P value = 0.014). Chronic pain was recorded in 7.9% vs. 16.9% of patients (P = 0.171) at Week 12 in the mirogabalin add-on vs. conventional treatment groups, respectively. Regarding activities of daily living (ADL) and quality of life (QOL), changes in Pain Disability Assessment Scale score and the EQ-5D-5L index value from baseline to Week 8 showed significant improvement in the mirogabalin add-on group vs. conventional treatment group (P < 0.001). The most common adverse events (AEs) in the mirogabalin add-on group were dizziness (12.7%), somnolence (7.9%), and urticaria (3.2%). Most AEs were mild or moderate in severity | ||
| 520 | |a CONCLUSIONS: Addition of mirogabalin to conventional therapy did not result in significant improvement in pain intensity based on VAS scores, but did result in significant improvement in ADL and QOL in patients with peripheral NeP after thoracic surgery | ||
| 520 | |a TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs071200053 (registered 17/11/2020) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic postsurgical pain | |
| 650 | 4 | |a Mirogabalin | |
| 650 | 4 | |a Post thoracotomy pain syndrome | |
| 650 | 4 | |a Postoperative neuropathic pain | |
| 650 | 4 | |a Thosracic surgery | |
| 650 | 7 | |a mirogabalin |2 NLM | |
| 650 | 7 | |a S7LK2KDM5U |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds |2 NLM | |
| 700 | 1 | |a Matsumoto, Keitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sano, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Furukawa, Katsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Shimoyama, Koichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kamohara, Ryotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kondou, Masamichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Norihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tabata, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shiosakai, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Nagayasu, Takeshi |e verfasserin |4 aut | |
| 700 | 0 | |a ADMIT-NeP Study group |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Ryoichiro |e investigator |4 oth | |
| 700 | 1 | |a Waseda, Ryuichi |e investigator |4 oth | |
| 700 | 1 | |a Nakamura, Akihiro |e investigator |4 oth | |
| 700 | 1 | |a Akao, Keiko |e investigator |4 oth | |
| 700 | 1 | |a Hatachi, Go |e investigator |4 oth | |
| 700 | 1 | |a Tagawa, Tsutomu |e investigator |4 oth | |
| 700 | 1 | |a Imai, Makoto |e investigator |4 oth | |
| 700 | 1 | |a Ikeda, Koei |e investigator |4 oth | |
| 700 | 1 | |a Hagiwara, Masaru |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 24(2024), 1 vom: 15. Jan., Seite 80 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:15 |g month:01 |g pages:80 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-023-11708-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 15 |c 01 |h 80 | ||